David CFA - Celularity Chief Officer
| CELUW Stock | USD 0.02 0.0004 1.79% |
Executive
David CFA is Chief Officer of Celularity
| Age | 54 |
| Address | 170 Park Avenue, Florham Park, NJ, United States, 07932 |
| Phone | 908 768 2170 |
| Web | https://www.celularity.com |
Celularity Management Efficiency
The company has return on total asset (ROA) of (0.1463) % which means that it has lost $0.1463 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5423) %, meaning that it generated substantial loss on money invested by shareholders. Celularity's management efficiency ratios could be used to measure how well Celularity manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -1.49 in 2024. Return On Capital Employed is likely to climb to -2.39 in 2024. At this time, Celularity's Non Currrent Assets Other are fairly stable compared to the past year. Total Current Assets is likely to climb to about 30 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 117.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Juan Avendano | Quantum Si incorporated | N/A | |
| SPHR GPHR | Humacyte | N/A | |
| Johan Denecke | Quantum Si incorporated | N/A | |
| Sabrina Osborne | Humacyte | N/A | |
| Sharmila MD | Celularity | N/A | |
| Tim Wilk | Celularity | N/A | |
| Ramji Krishnan | Celularity | N/A | |
| Alex Hutcheson | Quantum Si incorporated | N/A | |
| John Vieceli | Quantum Si incorporated | N/A | |
| Jeffry Keyes | Quantum Si incorporated | 51 | |
| Timothy Smith | Celularity | N/A | |
| Harold Alterson | Humacyte | N/A | |
| Katherine Atkinson | Quantum Si incorporated | N/A | |
| Yang MD | Humacyte | 58 | |
| Grace Johnston | Quantum Si incorporated | 41 | |
| Christian JD | Quantum Si incorporated | 53 | |
| Shamik MD | Humacyte | 51 | |
| CPA MS | Celularity | 62 | |
| Todd Bennett | Quantum Si incorporated | 54 | |
| William Scheessele | Humacyte | 52 | |
Management Performance
| Return On Equity | -1.54 | ||||
| Return On Asset | -0.15 |
Celularity Leadership Team
Elected by the shareholders, the Celularity's board of directors comprises two types of representatives: Celularity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celularity. The board's role is to monitor Celularity's management team and ensure that shareholders' interests are well served. Celularity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celularity's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carlos Ramirez, SVP Relations | ||
| Sharmila MD, Senior Safety | ||
| CFA CFA, Chief Officer | ||
| Tim Wilk, Senior Operations | ||
| Ramji Krishnan, Chief Officer | ||
| Bradley Glover, Ex COO | ||
| CPA MS, Treasurer | ||
| Stephen DPM, President Diseases | ||
| David CFA, Chief Officer | ||
| MBA MD, Chief VP | ||
| John Haines, Global EVP | ||
| Robert MD, CEO Founder | ||
| Beth Steinbrenner, Ex HR | ||
| Timothy Smith, Secretary | ||
| Keary Esq, Gen EVP | ||
| Anne Jones, Exec Officer | ||
| Kyle Esq, General VP |
Celularity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celularity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.54 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (2.64) % | ||||
| Operating Margin | (0.84) % | ||||
| Number Of Shares Shorted | 175.73 K | ||||
| Revenue | 22.77 M | ||||
| EBITDA | (35.91 M) | ||||
| Net Income | (196.29 M) | ||||
| Cash And Equivalents | 38 M | ||||
| Cash Per Share | 0.27 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.